PT3368572T - Anticorpos anti-pd-1 e composições - Google Patents
Anticorpos anti-pd-1 e composiçõesInfo
- Publication number
- PT3368572T PT3368572T PT167746916T PT16774691T PT3368572T PT 3368572 T PT3368572 T PT 3368572T PT 167746916 T PT167746916 T PT 167746916T PT 16774691 T PT16774691 T PT 16774691T PT 3368572 T PT3368572 T PT 3368572T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236341P | 2015-10-02 | 2015-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3368572T true PT3368572T (pt) | 2022-06-23 |
Family
ID=57042898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167746916T PT3368572T (pt) | 2015-10-02 | 2016-09-30 | Anticorpos anti-pd-1 e composições |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11034765B2 (pt) |
| EP (2) | EP4105235A1 (pt) |
| JP (1) | JP6875385B2 (pt) |
| KR (1) | KR102897330B1 (pt) |
| CN (1) | CN108290953B (pt) |
| AU (1) | AU2016333517B2 (pt) |
| BR (1) | BR112018006257A2 (pt) |
| CA (1) | CA3000564A1 (pt) |
| CO (1) | CO2018003500A2 (pt) |
| CY (1) | CY1125327T1 (pt) |
| DK (1) | DK3368572T3 (pt) |
| ES (1) | ES2924402T3 (pt) |
| HR (1) | HRP20221041T1 (pt) |
| HU (1) | HUE059788T2 (pt) |
| IL (1) | IL258214B2 (pt) |
| LT (1) | LT3368572T (pt) |
| MX (1) | MX2018003936A (pt) |
| MY (1) | MY190324A (pt) |
| PE (1) | PE20181044A1 (pt) |
| PL (1) | PL3368572T3 (pt) |
| PT (1) | PT3368572T (pt) |
| RS (1) | RS63490B1 (pt) |
| RU (1) | RU2750675C1 (pt) |
| SA (1) | SA518391262B1 (pt) |
| SG (1) | SG10201912943RA (pt) |
| SI (1) | SI3368572T1 (pt) |
| TW (1) | TWI751981B (pt) |
| WO (1) | WO2017055547A1 (pt) |
| ZA (1) | ZA201801852B (pt) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3283508T (pt) | 2015-04-17 | 2021-06-21 | Alpine Immune Sciences Inc | Proteínas imuno modulatórias com afinidades afináveis |
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| AU2016305697B2 (en) | 2015-08-11 | 2023-02-02 | WuXi Biologics Ireland Limited | Novel anti-PD-1 antibodies |
| CN107949573B (zh) | 2015-09-01 | 2022-05-03 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| KR20180054824A (ko) | 2015-09-29 | 2018-05-24 | 셀진 코포레이션 | Pd-1 결합 단백질 및 이의 사용 방법 |
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| MY198562A (en) | 2015-11-03 | 2023-09-05 | Janssen Biotech Inc | Antibodies specifically binding pd-1 and their uses |
| WO2017181148A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
| IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
| BR112019004733A2 (pt) | 2016-09-19 | 2019-05-28 | Celgene Corp | métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1 |
| DK3515938T3 (da) | 2016-09-21 | 2025-04-07 | Cstone Pharmaceuticals | Monoklonale antistoffer mod programmeret død 1 (pd-1) |
| BR112019008494A2 (pt) | 2016-11-02 | 2019-07-09 | Jounce Therapeutics Inc | anticorpos para pd-1 e usos dos mesmos |
| EA201991214A1 (ru) | 2016-11-18 | 2019-10-31 | Антитела против pd-1 и их композиции | |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| CN117586401A (zh) | 2017-01-20 | 2024-02-23 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其用途 |
| IL268781B2 (en) | 2017-03-16 | 2025-09-01 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| JP2020513009A (ja) | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療 |
| CN106939049B (zh) * | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| US11466084B2 (en) * | 2017-06-25 | 2022-10-11 | Systimmune, Inc. | Anti-PD-1 antibodies and methods of making and using thereof |
| EP4088783A1 (en) | 2017-08-01 | 2022-11-16 | Ab Studio Inc. | Bispecific antibodies and uses thereof |
| KR101917854B1 (ko) * | 2017-08-24 | 2018-11-12 | 한국콜마주식회사 | 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물 |
| EA202090974A1 (ru) | 2017-10-18 | 2020-08-05 | Элпайн Иммьюн Сайенсиз, Инк. | Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| TWI708787B (zh) | 2018-03-02 | 2020-11-01 | 美商美國禮來大藥廠 | Pd-1促效劑抗體及其用途 |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| IL310398A (en) | 2018-04-18 | 2024-03-01 | Xencor Inc | Proteins from heterodimeric il-15/il-15rα fc and their uses |
| BR112020022265A2 (pt) | 2018-05-07 | 2021-02-23 | Genmab A/S | método para tratar câncer em um indivíduo, e, estojo. |
| CN112739716B (zh) | 2018-05-07 | 2025-05-27 | 展马博联合股份有限公司 | 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法 |
| WO2019241758A1 (en) * | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| EP4349411A3 (en) | 2018-06-20 | 2024-06-19 | Incyte Corporation | Anti-pd-1 antibodies and uses thereof |
| JP7090204B2 (ja) * | 2018-07-19 | 2022-06-23 | イーライ リリー アンド カンパニー | 免疫チェックポイントを標的とする二重特異性抗体 |
| CN112424231B (zh) * | 2018-07-19 | 2022-09-13 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其剂量和用途 |
| MX2021001883A (es) * | 2018-08-16 | 2021-07-15 | Musc Found For Res Dev | Virus recombinantes del mixoma y usos de los mismos. |
| SG11202101904UA (en) * | 2018-09-14 | 2021-04-29 | Univ Leland Stanford Junior | Spd-1 variant - fc fusion proteins |
| CA3116188A1 (en) * | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| BR112021008122A8 (pt) * | 2018-10-31 | 2023-01-31 | Merck Sharp & Dohme | Cristais de anticorpo anti-pd-1 humano e métodos de uso dos mesmos |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| CN111349162A (zh) * | 2018-12-21 | 2020-06-30 | 神州细胞工程有限公司 | 人源化抗pd-1抗体及其用途 |
| WO2020127367A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Humanized anti-human-pd-1 antibody |
| EP3917579A4 (en) | 2019-01-28 | 2023-03-29 | AB Therapeutics, Inc. | SPECIFIC ANTIBODIES AND USES THEREOF |
| AR118619A1 (es) | 2019-04-10 | 2021-10-20 | Bio Thera Solutions Ltd | Anticuerpos de unión a pd-1 |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| JP7771749B2 (ja) | 2019-08-08 | 2025-11-18 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
| JP7662617B2 (ja) | 2019-09-06 | 2025-04-15 | レ ラボラトワール セルヴィエ | 抗ｃｄ７３抗体 |
| CN115916233A (zh) * | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
| CN112915202B (zh) * | 2019-12-06 | 2025-08-01 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| US20230348902A1 (en) * | 2020-08-10 | 2023-11-02 | Integral Molecular, Inc. | Methods and compositions for making antibody libraries and antibodies isolated from the same |
| KR20230060531A (ko) * | 2020-08-31 | 2023-05-04 | 바이오션, 인코포레이티드 | Pd-1에 결합하는 항체 및 이의 용도 |
| AU2021383611A1 (en) | 2020-11-17 | 2023-06-29 | Peter Maccallum Cancer Institute | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
| JP2024508658A (ja) * | 2021-02-04 | 2024-02-28 | ジェヌーヴ インク． | 抗ｐｄ－１抗体及びその用途 |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| CA3226924A1 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CN118451097A (zh) | 2021-08-16 | 2024-08-06 | 再生元制药公司 | 新型il27受体激动剂及其使用方法 |
| CA3233771A1 (en) | 2021-10-04 | 2023-04-13 | Les Laboratoires Servier | Cancer therapy targeting nkg2a |
| JP2024536383A (ja) | 2021-10-06 | 2024-10-04 | ジェンマブ エー／エス | 併用におけるｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤 |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| JP2025516596A (ja) | 2022-05-11 | 2025-05-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性結合分子プロタンパク質及びその使用 |
| IL316628A (en) | 2022-05-12 | 2024-12-01 | Genmab As | Binding agents capable of binding to CD27 in combination therapy |
| CN119451979A (zh) | 2022-05-27 | 2025-02-14 | 再生元制药公司 | 白细胞介素-2蛋白质原及其用途 |
| WO2023235848A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| AU2023325400A1 (en) | 2022-08-18 | 2025-02-27 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
| AU2023401158A1 (en) | 2022-12-01 | 2025-05-29 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| US20240270836A1 (en) | 2023-01-13 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| IL322890A (en) | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| AR132543A1 (es) * | 2023-04-28 | 2025-07-16 | Initial Therapeutics Inc | Compuestos, composiciones y métodos para la atenuación de la traducción en mamíferos de proteínas c-myc o n-myc de la familia de protooncogenes myc de factores de transcripción bhlh |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| WO2025106469A1 (en) | 2023-11-14 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Engineered heavy chain variable domains and uses thereof |
| WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
| US20250179137A1 (en) | 2023-12-05 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| WO2025199243A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Trivalent multispecific binding molecules and methods of use thereof |
| WO2025255480A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101105610B1 (ko) | 2006-08-17 | 2012-01-18 | 에프. 호프만-라 로슈 아게 | Ｃｃｒ５ 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트 |
| RU2459868C2 (ru) | 2007-03-01 | 2012-08-27 | Симфоген А/С | Способ клонирования когнатных антител |
| EP2331689A4 (en) | 2008-08-29 | 2012-10-31 | Symphogen As | METHOD OF CLONING AVIAN ORIGIN ANTIBODIES |
| CA2736816C (en) * | 2008-09-12 | 2018-05-22 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| JP2013532153A (ja) * | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3237446B1 (en) | 2014-12-22 | 2021-05-05 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
-
2016
- 2016-09-30 JP JP2018516765A patent/JP6875385B2/ja active Active
- 2016-09-30 RU RU2018115979A patent/RU2750675C1/ru active
- 2016-09-30 LT LTEPPCT/EP2016/073421T patent/LT3368572T/lt unknown
- 2016-09-30 ES ES16774691T patent/ES2924402T3/es active Active
- 2016-09-30 HR HRP20221041TT patent/HRP20221041T1/hr unknown
- 2016-09-30 AU AU2016333517A patent/AU2016333517B2/en active Active
- 2016-09-30 EP EP22174837.9A patent/EP4105235A1/en not_active Withdrawn
- 2016-09-30 EP EP16774691.6A patent/EP3368572B9/en active Active
- 2016-09-30 DK DK16774691.6T patent/DK3368572T3/da active
- 2016-09-30 HU HUE16774691A patent/HUE059788T2/hu unknown
- 2016-09-30 KR KR1020187011821A patent/KR102897330B1/ko active Active
- 2016-09-30 TW TW105131644A patent/TWI751981B/zh active
- 2016-09-30 SG SG10201912943RA patent/SG10201912943RA/en unknown
- 2016-09-30 US US15/765,337 patent/US11034765B2/en active Active
- 2016-09-30 SI SI201631586T patent/SI3368572T1/sl unknown
- 2016-09-30 PE PE2018000485A patent/PE20181044A1/es unknown
- 2016-09-30 IL IL258214A patent/IL258214B2/en unknown
- 2016-09-30 PL PL16774691.6T patent/PL3368572T3/pl unknown
- 2016-09-30 WO PCT/EP2016/073421 patent/WO2017055547A1/en not_active Ceased
- 2016-09-30 BR BR112018006257-0A patent/BR112018006257A2/pt active IP Right Grant
- 2016-09-30 CA CA3000564A patent/CA3000564A1/en active Pending
- 2016-09-30 RS RS20220762A patent/RS63490B1/sr unknown
- 2016-09-30 PT PT167746916T patent/PT3368572T/pt unknown
- 2016-09-30 MY MYPI2018701111A patent/MY190324A/en unknown
- 2016-09-30 CN CN201680069542.1A patent/CN108290953B/zh active Active
- 2016-09-30 MX MX2018003936A patent/MX2018003936A/es unknown
-
2018
- 2018-03-20 ZA ZA2018/01852A patent/ZA201801852B/en unknown
- 2018-04-02 SA SA518391262A patent/SA518391262B1/ar unknown
- 2018-04-02 CO CONC2018/0003500A patent/CO2018003500A2/es unknown
-
2022
- 2022-07-05 CY CY20221100455T patent/CY1125327T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258214A (en) | Antibodies - anti-pd-1 and preparations | |
| IL265844A (en) | Anti-lag-3 antibodies and preparations | |
| ZA201902265B (en) | Anti-pd-1 antibodies and their uses | |
| IL262176A (en) | Anti-tim-3 antibodies and preparations | |
| IL256295A (en) | Anti-ntb-a antibodies and related compositions and methods | |
| IL257062A (en) | New anti-pd-1 antibodies | |
| HUS2500024I1 (hu) | ANTI-PD-1 ellenanyagok | |
| IL255961B (en) | Anti-cd40 antibodies and uses thereof | |
| SG11201708223QA (en) | Compositions comprising a combination of an anti-pd-1 antibody and another antibody | |
| ZA201707138B (en) | Anti-ceacam6 antibodies and uses thereof | |
| HUE069391T2 (hu) | Antitest kompozíciók | |
| HK40007470A (en) | Anti-pd-1 antibodies and compositions |